抄録
As heparin cannot inhibit platelet function, there is a possible situation in hemodialysis in which another supplementary platelet inhibitor is required for successful anticoagulation. In this regard, prostaglandin (PG) E1 and D2 were evaluated as antiplatelet agents during hemodialysis.
Inhibitory effect of PGD2 on platelet aggregability in vitro was more potent than PGE1 by about 3 Times. Judging from adverse effects, PGD2 can be administered twice as much as PGE1 during hemodialysis. Consequently, more potent inhibitory activity on platelet can be expected clinically in PGD2 than PGE1 by 5 times. PGE1 can be used as a supportive agent fcr heparin. PGD2 can be expected as an agent for regional anticoagulation.
